The global Continuous Renal Replacement Therapy market was valued at USD 1,356.7 million in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. Several factors are driving this growth, including the increasing incidence of acute kidney injury (AKI), the rising number of sepsis cases, an expansion in the number of hospitals and urgent care centers, higher hospital admission rates, and consistent product innovations by leading market players. According to the American Kidney Fund, 37 million U.S. citizens are living with kidney disease, and 807,000 people in the U.S. are diagnosed with kidney failure. These statistics highlight the growing need for CRRT treatments, which are used to manage kidney failure and other kidney-related conditions.

The growing prevalence of kidney disease, especially in the aging population, is a major driver of demand for CRRT. Kidney diseases, such as Chronic Kidney Disease (CKD) and AKI, are leading causes of mortality worldwide. As these conditions increase in frequency, the need for effective renal replacement therapies, such as CRRT, grows. There has been significant progress in the technology used in CRRT devices, which has improved both clinical outcomes and the overall efficiency of treatment. Modern CRRT systems now feature automated data collection and standardized language protocols, enabling cross-institutional data comparisons. These advancements allow healthcare providers to better tailor treatments to individual patient needs, thereby improving patient outcomes and boosting the adoption of CRRT technologies. 

With advanced CRRT devices, clinicians are better able to monitor and manage treatment parameters, which helps to improve patient care. The integration of real-time data, automation, and precise delivery of therapy ensures that patients receive the most appropriate care, ultimately leading to better recovery rates and reduced mortality. As a result, hospitals and healthcare providers are increasingly adopting these advanced CRRT machines, which is expected to drive the market further. The rise in hospital admissions due to kidney-related illnesses, as well as the rapid expansion of urgent care centers, is also contributing to the increasing demand for CRRT devices. The healthcare industry's growing infrastructure and emphasis on critical care units and intensive care units (ICUs) is making CRRT more accessible to patients worldwide.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market 

Regional Insights:

North America

In 2022, North America held the largest revenue share of 36.5% of the global CRRT market. Several factors contribute to this dominance:

• Aging Population: The aging population in North America, especially in the U.S., is a key factor in the rising demand for CRRT. As people age, the incidence of kidney diseases such as Chronic Kidney Disease (CKD) and AKI increases, creating a higher need for renal replacement therapies.

• Prevalence of Kidney Disorders: According to the U.S. Department of Health and Human Services, over 1 in 7 U.S. adults is estimated to have CKD, and the incidence of kidney failure continues to rise. This widespread prevalence of kidney disease is a significant driver for the adoption of CRRT therapies in hospitals and healthcare systems.

• Lifestyle Factors: The growing adoption of sedentary lifestyles and unhealthy dietary habits in North America has led to an increase in lifestyle-related diseases such as hypertension, diabetes, and kidney dysfunction, all of which contribute to the rising demand for CRRT.

• Technological Advancements and Healthcare Infrastructure: The high adoption of cutting-edge healthcare technologies, coupled with an extensive healthcare infrastructure, makes North America a leader in the CRRT market. Hospitals and urgent care centers are increasingly equipped with advanced CRRT machines, further boosting market growth.

Asia Pacific 

The Asia Pacific region is projected to grow at the fastest CAGR of 9.8% over the forecast period. Several factors contribute to this rapid growth:

• Increasing Prevalence of Chronic Diseases: The rising incidence of diabetes, CKD, and hypertension in countries like China, India, and Japan is driving the demand for CRRT solutions. These chronic conditions are major risk factors for kidney failure, creating a pressing need for effective renal replacement therapies.

• Growing Healthcare Expenditure: The rising investment in healthcare infrastructure and increased healthcare spending in Asia Pacific countries are also contributing to market growth. Governments in the region are increasingly focusing on improving healthcare access and quality, especially in critical care and nephrology.

• Regulatory Support: In China, the government has introduced favorable policies such as the reduction in Value Added Tax (VAT) for medical manufacturing companies, which has encouraged the growth of the medical devices industry. These policies have made China an attractive market for medical device manufacturers, including those involved in CRRT solutions.

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

• The global topical scar treatment market size was estimated at USD 1.69 billion in 2024 and is expected to grow at a CAGR of 11.9% from 2025 to 2030.

• The global demineralized bone matrix market size was estimated at USD 1.24 billion in 2024 and is projected to grow at a CAGR of 5.9% from 2025 to 2030.

Key Companies & Market Share Insights:

As demand for CRRT products rises, global manufacturers are accelerating production while also focusing on cost-effective solutions. Some notable companies and their activities in the CRRT market include:

• Nipro Corporation: In March 2022, Nipro, a leader in renal care products, launched the SURDIAL DX system. This futuristic hemodialysis system is designed to optimize dialysis treatment, making it more efficient and patient-friendly. By improving treatment quality, Nipro aims to strengthen its position in the CRRT market.

• Baxter International: In April 2022, Baxter International received FDA 510(k) clearance for its ST set, a product used in continuous renal replacement therapy. The ST set is pre-connected, uses a semipermeable membrane to purify blood, and is compatible with PrisMax or Prismaflex systems. This new clearance underscores Baxter's commitment to innovation and expanding its CRRT product line.

• Fresenius Medical Care: In June 2021, Fresenius Medical Care inaugurated a training center in Korea, aimed at supporting education for healthcare professionals in areas such as critical care, renal care, and treatment strategies. By focusing on training healthcare providers, Fresenius seeks to improve the quality of care and patient outcomes, thus driving the demand for CRRT therapies.

Key Continuous Renal Replacement Therapy Companies:

• B. Braun Melsungen AG

• Baxter International, Inc.

• Fresenius Medical Care AG & Co. KGaA

• Asahi Kasei Corporation

• NIPRO Corporation

• Toray Medical Co., Ltd

• NxStage Medical, Inc.

• Medtronic PLC

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.